SCOPE of Pain: An Evaluation of an Opioid Risk Evaluation and Mitigation Strategy Continuing Education Program

Objective. Due to the high prevalence of prescription opioid misuse, the US Food and Drug Administration (FDA) mandated a Risk Evaluation and Mitigation Strategy (REMS) requiring manufacturers of extended-release/long-acting (ER/LA) opioid analgesics to fund continuing education based on a FDA Bluep...

Descripción completa

Detalles Bibliográficos
Autores principales: Alford, Daniel P., Zisblatt, Lara, Ng, Pamela, Hayes, Sean M., Peloquin, Sophie, Hardesty, Ilana, White, Julie L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
EDUCATION & TRAINING SECTION
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718419/
https://www.ncbi.nlm.nih.gov/pubmed/26304703
http://dx.doi.org/10.1111/pme.12878

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718419/
https://www.ncbi.nlm.nih.gov/pubmed/26304703
http://dx.doi.org/10.1111/pme.12878

Ejemplares similares